PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling.

Autor: Rosen MB; U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Integrated Systems Toxicology Division, USA. Electronic address: rosen.mitch@epa.gov., Das KP; Toxicology Assessment Division, Research Triangle Park, NC, USA. Electronic address: das.kaberi@epa.gov., Rooney J; U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Integrated Systems Toxicology Division, USA. Electronic address: rooney.john@epa.gov., Abbott B; Toxicology Assessment Division, Research Triangle Park, NC, USA. Electronic address: abbott.barbara@epa.gov., Lau C; Toxicology Assessment Division, Research Triangle Park, NC, USA. Electronic address: lau.christopher@epa.gov., Corton JC; U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Integrated Systems Toxicology Division, USA. Electronic address: corton.chris@epa.gov.
Jazyk: angličtina
Zdroj: Toxicology [Toxicology] 2017 Jul 15; Vol. 387, pp. 95-107. Date of Electronic Publication: 2017 May 27.
DOI: 10.1016/j.tox.2017.05.013
Abstrakt: Perfluoroalkyl acids (PFAAs) are ubiquitous and persistent environmental contaminants. Compounds such as perfluoroocanoic acid (PFOA), perfluorooctane sulfonate (PFOS), perfluorononanoic acid (PFNA), and perfluorohexane sulfonate (PFHxS) are readily found in the tissues of humans and wildlife. While PFOA and PFOS have been the subject of numerous studies since they were first described over a decade ago, less is known about the biological activity of PFHxS and PFNA. Most PFAAs are activators of peroxisome proliferator-activated receptor α (PPARα), although the biological effects of these compounds are likely mediated by other factors in addition to PPARα. To evaluate the effects of PFHxS and PFNA, male wild-type and Pparα-null mice were dosed by oral gavage with PFHxS (3 or 10mg/kg/day), PFNA (1 or 3mg/kg/day), or vehicle for 7days, and liver gene expression was evaluated by full-genome microarrays. Gene expression patterns were then compared to historical in-house data for PFOA and PFOS in addition to the experimental hypolipidemic agent, WY-14,643. While WY-14,643 altered most genes in a PPARα-dependent manner, approximately 11-24% of regulated genes in PFAA-treated mice were independent of PPARα. The possibility that PFAAs regulate gene expression through other molecular pathways was evaluated. Using data available through a microarray database, PFAA gene expression profiles were found to exhibit significant similarity to profiles from mouse tissues exposed to agonists of the constitutive activated receptor (CAR), estrogen receptor α (ERα), and PPARγ. Human PPARγ and ERα were activated by all four PFAAs in trans-activation assays from the ToxCast screening program. Predictive gene expression biomarkers showed that PFAAs activate CAR in both genotypes and cause feminization of the liver transcriptome through suppression of signal transducer and activator of transcription 5B (STAT5B). These results indicate that, in addition to activating PPARα as a primary target, PFAAs also have the potential to activate CAR, PPARγ, and ERα as well as suppress STAT5B.
(Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: